Therapeutic Response

v::ALK status confers therapeutic sensitivity to Crizotinib in patients with Inflammatory Myofibroblastic Tumor.

Statements

Source and description
Xalkori (crizotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).
Xalkori (crizotinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.